Documente Academic
Documente Profesional
Documente Cultură
[2]
Frampton J.E: QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in
patients with chronic obstructive pulmonary disease. Drugs. 2014 Mar; 74(4):465-8;
[3]
Kaplan A, Chapman K.R., Anees S.M., Mayers I, Rochdi D, Djandji M, Préfontaine D, McIvor A: Real-
life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in
patients with symptomatic COPD: the POWER study. Int J Chron Obstruct Pulmon Dis. 2019 Jan 18; 14:249-260;
[4]
Philip O’Hagan, Juergen Dederichs, Boomi Viswanad, Matthias Gasser, Susann Walda: Patient
preference for a maintenance inhaler in chronic obstructive pulmonary disease: a comparison of Breezhaler and
Respimat. J Thorac Dis. 2018 Oct; 10(10): 5727–5735;
[5]
https://www.ema.europa.eu/en/medicines/human/EPAR/ultibro-breezhaler